Lomitapide

證據等級: L5

預測適應症: 10 個

Lomitapide: From Homozygous Familial Hypercholesterolemia to Macrothrombocytopenia With Mitral Valve Insufficiency

One-Sentence Summary

Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor originally approved (as Juxtapid/Lojuxta) for homozygous familial hypercholesterolemia (HoFH). TxGNN's top-ranked new-indication prediction, macrothrombocytopenia with mitral valve insufficiency, carries a 99.92% model score but is currently backed by zero clinical trials and zero publications — the signal exists only inside the model.

Quick Overview

Item	Content
Original Indication	Homozygous Familial Hypercholesterolemia (HoFH) — inferred from trial/literature evidence (Juxtapid/Lojuxta); not present in structured `taiwan_regulatory` licensing data
Predicted New Indication	Macrothrombocytopenia with Mitral Valve Insufficiency
TxGNN Prediction Score	99.92%
Evidence Level	L5 (model prediction only)
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Lomitapide's mechanism is well characterized in the underlying trial/literature evidence even though the structured original_moa field is a data gap: it inhibits MTP in the liver and intestine, blocking assembly and secretion of apoB-containing lipoproteins (VLDL, chylomicrons), which lowers LDL‑C, apoB and total cholesterol. This is the basis for its approval in HoFH.

Macrothrombocytopenia with mitral valve insufficiency is a rare, largely genetic platelet/connective-tissue disorder. There is no established biological pathway linking MTP-mediated lipoprotein assembly to platelet size regulation or mitral valve structure, and the evidence pack's own rationale explicitly flags this: "無機轉證據。屬罕見遺傳性巨大血小板症候群，與 MTP 抑制無已知關聯，零試驗零文獻，純模型預測" (no mechanistic evidence; a rare hereditary macrothrombocytopenia syndrome with no known relationship to MTP inhibition; zero trials, zero literature, pure model prediction).

This pattern repeats across ranks 1–8 and 10 in this evidence pack — all platelet/coagulation disorders (hereditary thrombocytopenia, dense granule disease, pseudo-von Willebrand disease, Glanzmann thrombasthenia, platelet storage pool deficiency, etc.) score extremely high (>99.5%) with no supporting mechanism, trials, or literature. This clustering, combined with the fact that a mechanistically sensible indication (hyperlipoproteinemia — rank 9, which is actually lomitapide's own original approval territory) scores lower than these implausible candidates, suggests a knowledge-graph embedding artifact — likely driven by co-occurrence of lipid and hematologic parameters in shared patient records — rather than a genuine pharmacological signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Lomitapide has no marketing authorizations on file for Finland (0 licenses recorded; market status: not marketed).

Safety Considerations

Formal safety fields (key warnings, contraindications, drug interactions) are marked as data gaps in the source evidence pack (DG001, Blocking severity) — please refer to the package insert for detailed safety information.

Note: Although not captured in the structured safety fields, the repurposing-rationale text for a related predicted indication explicitly notes that lomitapide carries a known hepatotoxicity risk and is contraindicated in pregnant and neonatal populations — relevant context for any future evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication (macrothrombocytopenia with mitral valve insufficiency) has no mechanistic plausibility, no clinical trials, and no literature support — evidence level L5, decision stage S0. The same holds for 8 of the other 9 ranked candidates in this pack. The only candidate with strong evidence, hyperlipoproteinemia (L1, 12 trials including pivotal Phase 3 studies, 19 publications), is not a genuine repurposing opportunity — it reflects lomitapide's existing approved indication (HoFH) resurfacing under a broader disease-ontology term, not a novel use.

To proceed, the following is needed:

TFDA/Fimea package insert data (DG001, Blocking) before any safety evaluation can begin
Verified DrugBank MOA record (DG002) to properly ground mechanistic-link analysis
A model/embedding-level audit of why TxGNN concentrates high scores on unrelated platelet/coagulation-disorder nodes for an MTP inhibitor
If pursuing lipid-adjacent extensions is of interest, evaluate label-adjacent conditions such as familial chylomicronemia syndrome (PMID 36152419) as an off-label extension review — not as a novel repurposing candidate from this prediction set
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.